Bobby Daly, MD, MBA, and Ray D Page, DO, PhD, discuss the ramifications of clinical pathway vendor conflicts of interest and the potential issues of full transparency on the part of committee members.
To better understand how clinical pathways are developed and executed in cardiovascular care, Journal of Clinical Pathways spoke with researchers from University of Chicago Medicine (Chicago, IL), who developed a multifaceted Acutely Decompensated Heart Failure Clinical Pathway program to reduce inpatient readmission rates.
How Christiana Care and Strata Precision Oncology Are Making No-Cost Tumor Profiling and DNA Sequencing More Accessible
To gain more insight into this partnership and the future of tumor profiling in cancer treatment, Journal of Clinical Pathways spoke with Nicholas J Petrelli, MD, FACS, Bank of America-endowed medical director of Christiana Care’s Helen F. Graham Cancer Center & Research Institute.
John Danaher, MD, President of Clinical Solutions, Elsevier, and Kathy Lokay, President and CEO, Via Oncology, speak on behalf of their respective companies regarding Elsevier's recent acquisition of Via Oncology.
Tanner Caverly, MD, MPH, explains the impact of high false-positive rates following initial low-dose CT screening for lung cancer and the associated cost implications.
To gain a better understanding of the newly available options for patients with this hematologic malignancy, Journal of Clinical Pathways spoke with Natalie S Callander, MD, professor of hematology/oncology at University of Wisconsin School of Medicine and Public Health (Madison, WI).
Journal of Clinical Pathways recently spoke with Dr Page about the continued validation of the VeriStrat test, the role of testing within clinical pathways, and their effect on the OCM.
Journal of Clinical Pathways spoke with Editorial Advisory Board member Ayman Elfiky, MD, MSc, MPH, about how clinical pathways are used at Dana-Farber Cancer Institute (Boston, MA).
Journal of Clinical Pathways spoke with Dr Miller about a recent blog post, and how he sees future payment models adapting to an influx of costly new therapies as they enter the marker.
To best understand how a large research hospital implements clinical pathways in day-to-day practice, Journal of Clinical Pathways spoke with Editorial Advisory Board Member David A Hughes, who serves as the director of the clinical pathways program at Seattle Cancer Care Alliance.